BRENTWOOD, Tenn. / Sep 03, 2024 / Business Wire / Ardent Health (NYSE: ARDT) today announced the appointment of Dave Styblo as senior vice president of investor relations. In his new role, Styblo will oversee Ardent’s investor relations program and serve as the primary liaison with investors, analysts and financial partners.
Styblo brings more than 20 years of investment experience, including time as a sell-side analyst covering the healthcare industry. He previously served as a senior vice president at Jefferies for more than a decade as an equity research analyst with a focus on healthcare services and managed care stocks.
Most recently, Styblo served as an independent investor relations advisor to healthcare companies. He began his career as a sell-side research associate at JPMorgan Chase/Bear Stearns & Co. Styblo is a graduate of the University of Virginia.
“Dave’s deep experience and industry knowledge will be a great asset as we continue to build strong relationships and share the Ardent story across the investment community,” said Ardent Health Chief Financial Officer Alfred Lumsdaine. “We are excited to welcome him to Ardent as we begin this new chapter as a public company.”
About Ardent Health
Ardent Health (NYSE: ARDT) is a leading provider of healthcare in growing mid-sized urban communities across the U.S. With a focus on people and investments in innovative services and technologies, Ardent is passionate about making healthcare better and easier to access. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and more than 200 sites of care with over 1,700 affiliated providers across six states. For more information, please visit www.ardenthealth.com.
Last Trade: | US$16.61 |
Daily Volume: | 202,713 |
November 06, 2024 August 14, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB